GLAND vs LYKALABS: Stock Comparison
GLAND PHARMA is the larger company by market capitalisation. GLAND PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth, while LYKALABS shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAND leads 10; LYKALABS leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAND | LYKALABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAND | LYKALABS |
|---|---|---|
| Live Price | ₹2,922.3 | ₹74.83 |
| Day Change | -0.83% | 1.19% |
| Volume | 3.89 L | 88,556 |
| 52-Week High | ₹3,042 | ₹101.9 |
| 52-Week Low | ₹1,573.6 | ₹44.1 |
| Distance from 52W High | -3.93% | -26.57% |
Valuation
| Metric | GLAND | LYKALABS |
|---|---|---|
| Market Cap | ₹48,333 Cr | ₹298 Cr |
| P/E Ratio | 42.78x | 0x |
| P/B Ratio | 4.66x | 2.67x |
| EPS | ₹22.09 | ₹0.58 |
| Book Value | ₹627.91 | ₹25.12 |
| Dividend Yield | 0.68% | 0% |
Growth
| Metric | GLAND | LYKALABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 22.3% | 0% |
| EPS Growth (TTM YoY) | 96.4% | 0% |
| Qtr Sales Growth | -28.53% | 0% |
| Qtr Profit Growth | 14.96% | 2.62% |
Profitability & Leverage
| Metric | GLAND | LYKALABS |
|---|---|---|
| ROE | 12.02% | -11.49% |
| ROCE | 17.2% | -6.25% |
| Net Margin | 16.18% | -7.81% |
| Operating Margin | 38.8% | -6.71% |
| Debt to Equity | 0x | 0.53x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLAND | LYKALABS |
|---|---|---|
| Promoter Holding | 51.77% | 58.45%▲ 0.29 pp |
| FII Holding | 8.74%▲ 1.44 pp | 0.17%▼ 0.12 pp |
| DII Holding | 30.44%▼ 2.91 pp | 0.66%▼ 0.01 pp |
| Public Holding | 9.05%▲ 1.53 pp | 40.72%▼ 0.16 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAND PHARMA and LYKALABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.